Phospholipid Metabolites in Recurrent Glioblastoma: In Vivo Markers Detect Different Tumor Phenotypes before and under Antiangiogenic Therapy

PLoS ONE

Volumn 8, Issue 3, 2013, Pages

  Hattingen, Elke ^a   Bähr, Oliver ^a   Rieger, Johannes ^a   Blasel, Stella ^a   Steinbach, Joachim ^a   Pilatus, Ulrich ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; CHOLINE; GLYCEROETHANOLAMINE; GLYCEROPHOSPHORYLCHOLINE; IRINOTECAN; PHOSPHOETHANOLAMINE; PHOSPHOLIPID; PHOSPHORYLCHOLINE; TEMOZOLOMIDE; TUMOR MARKER; UNCLASSIFIED DRUG;

ADJUVANT THERAPY; ADULT; AGED; ANTIANGIOGENIC THERAPY; ARTICLE; CANCER ADJUVANT THERAPY; CHEMORADIOTHERAPY; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; FEMALE; GLIOBLASTOMA; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MALE; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OVERALL SURVIVAL; PHENOTYPE; PHOSPHOLIPID METABOLISM; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; PREDICTIVE VALUE; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTON NUCLEAR MAGNETIC RESONANCE; RECURRENT CANCER; SIGNAL TRANSDUCTION; SURVIVAL TIME; TREATMENT DURATION; TREATMENT RESPONSE; TUMOR GROWTH; TUMOR RECURRENCE;

ADULT; AGED; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; BRAIN NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; GLIOBLASTOMA; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PHOSPHOLIPIDS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 84874763659     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0056439     Document Type: Article

References (58)

1. Macdonald D, Cascino T, Schold SJ, Cairncross J, (1990) Response criteria for phase II studies of supratentorial malignant glioma. J Clin Oncol 8: 1277-1280.
2. Norden AD, Drappatz J, Muzikansky A, David K, Gerard M, et al. (2008) An exploratory survival analysis of anti-angiogenic therapy for recurrent malignant glioma. J Neurooncol 92: 149-155.
3. Hygino da Cruz LC Jr, Rodriguez I, Domingues RC, Gasparetto EL, Sorensen AG, (2011) Pseudoprogression and pseudoresponse: imaging challenges in the assessment of posttreatment glioma. AJNR Am J Neuroradiol 32: 1978-1985.
4. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, et al. (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol 27: 4733-4740.
5. Xu T, Chen J, Lu Y, Wolff JE, (2010) Effects of bevacizumab plus irinotecan on response and survival in patients with recurrent malignant glioma: a systematic review and survival-gain analysis. BMC Cancer 10: 252 Review.
6. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, et al. (2010) Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol 28: 1963-1972.
7. Oh J, Henry RG, Pirzkall A, Lu Y, Li X, et al. (2004) Survival analysis in patients with glioblastoma multiforme: predictive value of choline-to-N-acetylaspartate index, apparent diffusion coefficient, andrelative cerebral blood volume. J Magn Reson Imaging 19: 546-554.
8. Pirzkall A, Li X, Oh J, Chang S, Berger MS, et al. (2004) 3D MRSI for resected high-grade gliomas before RT: tumor extent according to metabolic activity in relation to MRI. Int J Radiat Oncol Biol Phys 59: 126-137.
9. Hattingen E, Jurcoane A, Bähr O, Rieger J, Magerkurth J, et al. (2011) Bevacizumab impairs oxidative energy metabolism and shows antitumoral effects in recurrent glioblastomas: a 31P/1H MRSI and quantitative magnetic resonance imaging study. Neuro Oncol 13: 1349-1363.
10. Podo F, (1999) Tumour phospholipid metabolism. NMR Biomed 12: 413-439 Review.
11. Herminghaus S, Pilatus U, Möller-Hartmann W, Raab P, Lanfermann H, et al. (2002) Increased choline levels coincide with enhanced proliferative activity of human neuroepithelial brain tumors. NMR Biomed 15: 385-392.
12. Kim H, Catana C, Ratai EM, Andronesi OC, Jennings DL, et al. (2011) Serial magnetic resonance spectroscopy reveals a direct metabolic effect of cediranib in glioblastoma. Cancer Res 71: 3745-3752.
13. Glunde K, Jie C, Bhujwalla ZM, (2006) Mechanisms of indomethacin-induced alterations in the choline phospholipid metabolism of breast cancer cells. Neoplasia 8: 758-771.
14. Sterin M, Cohen JS, Mardor Y, Berman E, Ringel I, (2001) Levels of phospholipid metabolites in breast cancer cells treated with antimitotic drugs: a 31P-magnetic resonance spectroscopy study. Cancer Res 61: 7536-7543.
15. Mirbahai L, Wilson M, Shaw CS, McConville C, Malcomson RD, et al. (2011) 1H magnetic resonance spectroscopy metabolites as biomarkers for cell cycle arrest and cell death in rat glioma cells. Int J Biochem Cell Biol 43: 990-1001.
16. Glunde K, Bhujwalla ZM, Ronen SM, (2011) Choline metabolism in malignant transformation. Nat Rev Cancer 11: 835-848 review.
17. Gillies RJ, Barry JA, Ross BD, (1994) In vitro and in vivo 13C and 31P NMR analyses of phosphocholine metabolism in rat glioma cells. Magn Reson Med 32: 310-318.
18. Aiken NR, Gillies RJ, (1996) Phosphomonoester metabolism as a function of cell proliferative status and exogenous precursors. Anticancer Res 16: 1393-1397.
19. Segebarth CM, Balériaux DF, Arnold DL, Luyten PR, den Hollander JA, (1987) MR image-guided P-31 MR spectroscopy in the evaluation of brain tumor treatment. Radiology 165: 215-219.
20. Heindel W, Bunke J, Glathe S, Steinbrich W, Mollevanger L, (1988) Combined 1H-MR imaging and localized 31P-spectroscopy of intracranial tumors in 43 patients. J Comput Assist Tomogr 12: 907-916.
21. Cadoux-Hudson TA, Blackledge MJ, Rajagopalan B, Taylor DJ, Radda GK, (1989) Human primary brain tumour metabolism in vivo: a phosphorus magnetic resonance spectroscopy study. Br J Cancer 60: 430-436.
22. Sutton LN, Lenkinski RE, Cohen BH, Packer RJ, Zimmerman RA, (1990) Localized 31P magnetic resonance spectroscopy of large pediatric brain tumors. J Neurosurg 72: 65-70.
23. Hubesch B, Sappey-Marinier D, Roth K, Meyerhoff DJ, Matson GB, et al. (1990) P-31 MR spectroscopy of normal human brain and brain tumors. Radiology 174: 401-409.
24. Rutter A, Hugenholtz H, Saunders JK, Smith IC, (1995) One-dimensional phosphorus-31 chemical shift imaging of human brain tumors. Invest Radiol 30: 359-66.
25. Maintz D, Heindel W, Kugel H, Jaeger R, Lackner KJ, (2002) Phosphorus-31 MR spectroscopy of normal adult human brain and brain tumours. NMR Biomed 15: 18-27.
26. Luyten PR, Bruntink G, Sloff FM, Vermeulen JW, van der Heijden JI, et al. (1989) Broadband proton decoupling in human 31P NMR spectroscopy. NMR Biomed 1: 177-83.
27. Albers MJ, Krieger MD, Gonzalez-Gomez I, Gilles FH, McComb JG, et al. (2005) Proton-decoupled 31P MRS in untreated pediatric brain tumors. Magn Reson Med 53: 22-29.
28. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, et al. (2005) MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol 26: 2466-2474.
29. Vanhamme L, van den Boogaart A, Van Huffel S, (1997) Improved method for accurate and efficient quantification of MRS data with use of prior knowledge. J Magn Reson 129: 35-43.
30. Provencher SW, (1993) Estimation of metabolite concentrations from localized in vivo proton NMR spectra. Magn Reson Med 30: 672-679.
31. Kreis R, (2004) Issues of spectral quality in clinical 1H-magnetic resonance spectroscopy and a gallery of artifacts. NMR Biomed 17: 361-381.
32. Hattingen E, Pilatus U, Franz K, Zanella FE, Lanfermann H, (2007) Evaluation of optimal echo time for 1H-spectroscopic imaging of brain tumors at 3 Tesla. J Magn Reson Imaging 26: 427-431.
33. Aoyama C, Liao H, Ishidate K, (2004) Structure and function of choline kinase isoforms in mammalian cells. Prog Lipid Res 43: 266-281.
34. Glunde K, Bhujwalla ZM, (2007) Choline kinase alpha in cancer prognosis and treatment. Lancet Oncol 8: 855-857.
35. Vanpouille C, Le Jeune N, Kryza D, Clotagatide A, Janier M, et al. (2009) Influence of multidrug resistance on (18)F-FCH cellular uptake in a glioblastoma model. Eur J Nucl Med Mol Imaging 36: 1256-1264.
36. Glunde K, Shah T, Winnard PT Jr, Raman V, Takagi T, et al. (2008) Hypoxia regulates choline kinase expression through hypoxia-inducible factor-1 alpha signaling in a human prostate cancer model. Cancer Res 68: 172-180.
37. Cuadrado A, Carnero A, Dolfi F, Jimenez B, Lacal JC, (1993) Phosphorylcholine: a novel second messenger essential for mitogenic activity of growth factors. Oncogene 8: 2959-2968.
38. Stewart JD, Marchan R, Lesjak MS, Lambert J, Hergenroeder R, et al. (2012) Choline-releasing glycerophosphodiesterase EDI3 drives tumor cell migration and metastasis. Proc Natl Acad Sci U S A 109: 8155-8160.
39. Vance JE, (2008) Phosphatidylserine and phosphatidylethanolamine in mammalian cells: two metabolically related aminophospholipids. J Lipid Res 49: 1377-87.
40. Hirata FJ, Axelrod J, (1980) Phospholipid methylation and biological signal transmission. Science 209: 1082-1090.
41. Jensen JE, Drost DJ, Menon RS, Williamson PC, (2002) In vivo brain (31)P-MRS: measuring the phospholipid resonances at 4 Tesla from small voxels. NMR in biomedicine 15: 338-347.
42. Daly PF, Lyon RC, Faustino PJ, Cohen JS, (1987) Phospholipid metabolism in cancer cells monitored by 31P NMR spectroscopy. J Biol Chem 262: 14875-14878.
43. Maris JM, Evans AE, McLaughlin AC, D'Angio GJ, Bolinger L, et al. (1985) 31P nuclear magnetic resonance spectroscopic investigation of human neuroblastoma in situ. N Engl J Med 312: 1500-1505.
44. Kinoshita Y, Yokota A, Koga Y, (1994) Phosphorylethanolamine content of human brain tumors. Neurol Med Chir (Tokyo) 34: 803-806.
45. Kinoshita Y, Yokota A, (1997) Absolute concentrations of metabolites in human brain tumors using in vitro proton magnetic resonance spectroscopy. NMR Biomed 10: 2-12.
46. Wright AJ, Fellows GA, Griffiths JR, Wilson M, Bell BA, et al. (2010) Ex-vivo HRMAS of adult brain tumours: metabolite quantification and assignment of tumour. Mol Cancer 9: 66.
47. Venkatesh HS, Chaumeil MM, Ward CS, Haas-Kogan DA, James CD, et al. (2011) Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma. Neuro-oncology 14: 315-325.
48. Ross BD, Higgins RJ, Boggan JE, Knittel B, Garwood M, (1988) 31P NMR spectroscopy of the in vivo metabolism of an intracerebral glioma in the rat. Magn Reson Med 6: 403-417.
49. Narayana A, Kunnakkat SD, Medabalmi P, Golfinos J, Parker E, et al. (2012) Change in pattern of relapse after antiangiogenic therapy in high-grade glioma. Int J Radiat Oncol Biol Phys 82: 77-82.
50. Chamberlain MC, (2011) Radiographic patterns of relapse in glioblastoma. Journal of neuro-oncology 101: 319-323.
51. Wick A, Dorner N, Schafer N, Hofer S, Heiland S, et al. (2011) Bevacizumab does not increase the risk of remote relapse in malignant glioma. Ann Neurol 69: 586-592.
52. Bähr O, Hattingen E, Rieger J, Steinbach JP, (2011) Bevacizumab-induced tumor calcifications as a surrogate marker of outcome in patients with glioblastoma. Neuro Oncol 13: 1020-1029.
53. Cohen BA, Knopp EA, Rusinek H, Babb JS, Zagzag D, et al. (2005) Assessing global invasion of newly diagnosed glial tumors with whole-brain proton MR spectroscopy. AJNR Am J Neuroradiol 26: 2170-2177.
54. Kallenberg K, Bock HC, Helms G, Jung K, Wrede A, et al. (2009) Untreated glioblastoma multiforme: increased myo-inositol and glutamine levels in the contralateral cerebral hemisphere at proton MR spectroscopy. Radiology 253: 805-812.
55. McKnight TR, Dem BM, Vigneron DB, Lu Y, Berger MS, et al. (2002) Histopathological validation of a three-dimensional magnetic resonance spectroscopy index as a predictor of tumor presence. J Neurosurg 97: 794-802.
56. Dowling C, Bollen AW, Noworolski SM, McDermott MW, Barbaro NM, et al. (2001) Preoperative proton MR spectroscopic imaging of brain tumors: correlation with histopathologic analysis of resection specimens. AJNR Am J Neuroradiol 22: 604-612.
57. Guo J, Yao C, Chen H, Zhuang D, Tang W, et al. (2012) The relationship between Cho/NAA and glioma metabolism: implementation for margin delineation of cerebral gliomas. Acta Neurochir (Wien) 154: 1361-1370.
58. Klomp DW, Wijnen JP, Scheenen TW, Heerschap A, (2008) Efficient 1H to 31P polarization transfer on a clinical 3T MR system. Magn Reson Med 60: 1298-1305.